Shots:
- Cartography has entered into a strategic collaboration with Pfizer to discover tumor-selective antigens, leveraging Cartography’s ATLAS & SUMMIT platforms
- Under a multi-year deal, Cartography will discover & validate tumor-selective antigens in an undisclosed cancer, with Pfizer holding opt-in rights for research, development & commercialization; Cartography retains full ownership of its lead asset CBI-1214
- Cartography will receive ~$65M in upfront, near-term milestones, & option exercise payments, with ~$800M in additional development, regulatory & commercial milestones if all options are exercised, plus tiered royalties on net sales
Ref: Businesswire | Image: Cartography & Pfizer | Press Release
Related News: Adaptive Biotechnologies and Pfizer Sign Rheumatoid Arthritis TCR Target Discovery and Immune Data Licensing Deals
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
